YU63802A - Modulatori adenozinskih receptora - Google Patents
Modulatori adenozinskih receptoraInfo
- Publication number
- YU63802A YU63802A YU63802A YUP63802A YU63802A YU 63802 A YU63802 A YU 63802A YU 63802 A YU63802 A YU 63802A YU P63802 A YUP63802 A YU P63802A YU 63802 A YU63802 A YU 63802A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- receptor modulators
- adenosine receptor
- disease
- antiepileptics
- ischaemia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Ovaj pronalazak se odnosi na ciklična heteroaromatična jedinjenja koja sadrže najmanje jedan atom azota i na njihovu primenu u proizvodnji lekova za terapiju bolesti koje su u vezi sa modulatorima adenozinskih receptora, kao što su Alchajmerova bolest, Parkinsonova bolest, neurozaštita (neuroprotekcija), shizofrenija, anksioznost, bol, nedostaci respiracije, depresija, astma, alergijski odgovori, hipoksija, ishemija, iznenadni napad bolesti, zloupotreba supstanci, sedacija (smirenje) i ona mogu biti aktivna kao relaksanti mišića, antipsihotici, antiepileptici, antikonvulzanti (sredstva protiv grčeva) kardiozaštitni agensi.[The invention relates to cyclic heteroaromatic compounds, containing at least one nitrogen atom, and to their use in the manufacture of medicaments for the treatment of diseases, related to adenosine receptor modulators, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure, substance abuse, sedation and they may be active as muscle relaxants, antipsychotics, antiepileptics, anticonvulsants and cardioprotective agents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00103432 | 2000-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU63802A true YU63802A (sh) | 2005-06-10 |
Family
ID=8167888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU63802A YU63802A (sh) | 2000-02-25 | 2001-02-15 | Modulatori adenozinskih receptora |
Country Status (28)
Country | Link |
---|---|
US (1) | US6586441B2 (sh) |
EP (1) | EP1261327B1 (sh) |
JP (1) | JP4064671B2 (sh) |
KR (1) | KR100521735B1 (sh) |
CN (1) | CN1438890A (sh) |
AR (1) | AR035392A1 (sh) |
AT (1) | ATE293962T1 (sh) |
AU (1) | AU780527B2 (sh) |
BR (1) | BR0108611A (sh) |
CA (1) | CA2398274C (sh) |
CZ (1) | CZ20023199A3 (sh) |
DE (1) | DE60110391T2 (sh) |
ES (1) | ES2240449T3 (sh) |
HR (1) | HRP20020673A2 (sh) |
HU (1) | HUP0300029A2 (sh) |
IL (1) | IL150912A0 (sh) |
JO (1) | JO2286B1 (sh) |
MA (1) | MA26878A1 (sh) |
MX (1) | MXPA02008240A (sh) |
NO (1) | NO20024006D0 (sh) |
NZ (1) | NZ520241A (sh) |
PE (1) | PE20011259A1 (sh) |
PL (1) | PL203805B1 (sh) |
RU (1) | RU2277911C2 (sh) |
UY (1) | UY26598A1 (sh) |
WO (1) | WO2001062233A2 (sh) |
YU (1) | YU63802A (sh) |
ZA (1) | ZA200206077B (sh) |
Families Citing this family (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110075507A1 (en) * | 1997-10-24 | 2011-03-31 | Revalesio Corporation | Diffuser/emulsifier |
US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
AR023052A1 (es) * | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
NZ524101A (en) * | 2000-08-08 | 2004-11-26 | Ortho Mcneil Pharm Inc | Neuroprotective 2-pyridinamine compositions and related methods for reducing ischemic death of cells or neuronal cell death |
GB0100620D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10115922A1 (de) * | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
MXPA03009185A (es) | 2001-04-09 | 2004-02-17 | Neurosearch As | Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson. |
US6958328B2 (en) | 2001-04-18 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc | Arylindenopyridines and related therapeutic and prophylactic methods |
US6903109B2 (en) | 2001-04-18 | 2005-06-07 | Ortho-Muniel Pharmaceutical, Inc. | Arylindenopyridines and related therapeutic and prophylactic methods |
AU2002337498B2 (en) * | 2001-09-21 | 2006-08-10 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
TWI265164B (en) * | 2001-09-21 | 2006-11-01 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
TWI330183B (sh) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
HUE043353T2 (hu) | 2002-01-28 | 2019-08-28 | Kyowa Hakko Kogyo Kk | A2A receptor antagonisták mozgás zavarok kezelésében történõ alkalmazásra |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
US20040127510A1 (en) | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
TW200409629A (en) | 2002-06-27 | 2004-06-16 | Bristol Myers Squibb Co | 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors |
GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
AU2003249484A1 (en) * | 2002-07-22 | 2004-02-09 | Orchid Chemicals And Pharmaceuticals Ltd | Novel bio-active molecules |
AU2002950853A0 (en) * | 2002-08-19 | 2002-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compound and pharmaceutical use thereof |
ATE325115T1 (de) | 2002-08-19 | 2006-06-15 | Glaxo Group Ltd | Pyrimidinderivate als selektive cox-2-inhibitoren |
GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
ATE371656T1 (de) * | 2002-11-04 | 2007-09-15 | Vertex Pharma | Heteroaryl-pyrimidinderivate als jak-inhibitoren |
EA009027B1 (ru) * | 2002-12-16 | 2007-10-26 | Мицубиси Фарма Корпорейшн | Производные 3-замещенного-4-пиримидона |
RS20050532A (en) * | 2003-01-14 | 2007-12-31 | Arena Pharmaceuticals Inc., | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
SI1599468T1 (sl) * | 2003-01-14 | 2008-02-29 | Arena Pharm Inc | 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije |
UA92450C2 (ru) * | 2003-01-14 | 2010-11-10 | Арена Фармасьютикалз, Инк. | 1,2,3-тризамещенные арильные и гетероарильные производные как модуляторы метаболизма, профилактика и лечение расстройств, связанных с ним, таких как диабет и гипергликемия |
TWI357408B (en) * | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
EP1615930A2 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA, Inc. | Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagonists |
EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
EP1505064A1 (en) * | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
CN1878761A (zh) * | 2003-10-03 | 2006-12-13 | 奥索-麦克尼尔药品公司 | 芳基茚并吡啶和芳基茚并嘧啶及其作为腺苷A2a受体拮抗剂的用途 |
GB0323138D0 (en) * | 2003-10-03 | 2003-11-05 | Chang Lisa C W | Pyrimidines substituted in the 2,4,6 positions and their different uses |
GB0323137D0 (en) * | 2003-10-03 | 2003-11-05 | Chang Lisa C W | 2,4,6- Trisubstituted pyrimidines and their different uses |
EP1670460B1 (en) | 2003-10-10 | 2014-11-26 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
US7582645B2 (en) | 2003-10-10 | 2009-09-01 | Bayer Pharmaceuticals Corporation | Pyrimidine derivatives for treatment of hyperproliferative disorders |
WO2005040135A1 (ja) * | 2003-10-24 | 2005-05-06 | Ono Pharmaceutical Co., Ltd. | 抗ストレス薬およびその医薬用途 |
BRPI0415863A (pt) * | 2003-10-27 | 2007-01-09 | Astellas Pharma Inc | derivados pirazina e seus usos farmacêuticos |
WO2005054239A1 (en) * | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
UA83101C2 (en) * | 2003-12-15 | 2008-06-10 | Алмирал Аг | 2,6-bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
WO2005060969A1 (en) * | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Pyrimidines with tie2 (tek) activity |
CN1989131A (zh) | 2004-03-30 | 2007-06-27 | 希龙公司 | 取代的噻吩衍生物用作抗癌药 |
JP4794200B2 (ja) * | 2004-04-30 | 2011-10-19 | 大塚製薬株式会社 | 4−アミノ−5−シアノピリミジン誘導体 |
GB0416168D0 (en) * | 2004-07-20 | 2004-08-18 | Vernalis Cambridge Ltd | Pyrmidothiophene compounds |
DE102004042607A1 (de) * | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
BRPI0515482A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e seus usos como agentes terapêuticos |
MX2007003325A (es) | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa. |
AR051094A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
EP1830837B1 (en) | 2004-09-20 | 2013-09-04 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
AU2005286728A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
AR051090A1 (es) | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
RU2007110731A (ru) * | 2004-09-23 | 2008-10-27 | Редди Юс Терапевтикс | Новые соединения пиримидина, способ их получения и содержащие их композиции |
WO2006041404A1 (en) * | 2004-10-15 | 2006-04-20 | Astrazeneca Ab | Substituted amino-compounds and uses thereof |
US20090062282A1 (en) * | 2004-10-15 | 2009-03-05 | Astrazeneca Ab | Substituted Amino-Pyrimidones and Uses Thereof |
WO2006059103A2 (en) * | 2004-12-03 | 2006-06-08 | Peakdale Molecular Limited | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products |
EP1888565B1 (en) * | 2005-04-11 | 2011-03-23 | Almirall, S.A. | 2, 6-di (hetero) aryl -4-amido-pyrimidines as adenosine receptor antagonists |
AR053712A1 (es) * | 2005-04-18 | 2007-05-16 | Neurogen Corp | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) |
JP2009513563A (ja) | 2005-06-03 | 2009-04-02 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体 |
ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
JP2009515950A (ja) * | 2005-11-15 | 2009-04-16 | アストラゼネカ・アクチエボラーグ | 新規な2−アミノピリミジン誘導体およびその使用 |
EP1951680A4 (en) * | 2005-11-15 | 2011-08-10 | Astrazeneca Ab | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE |
DE102006008880A1 (de) * | 2006-02-27 | 2007-09-06 | Merck Patent Gmbh | Aminopyrimidinderivate |
CA2644996A1 (en) * | 2006-03-02 | 2007-09-13 | Cv Therapeutics, Inc. | A2a adenosine receptor antagonists |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
EP2030971B1 (en) | 2006-06-20 | 2011-10-12 | Ishihara Sangyo Kaisha, Ltd. | Pest control agent containing novel pyridyl-methanamine derivative or salt thereof |
DE102006042143A1 (de) * | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
DE102006044696A1 (de) | 2006-09-22 | 2008-03-27 | Bayer Healthcare Ag | 3-Cyano-5-thiazaheteroaryl-dihydropyridine und ihre Verwendung |
US7985745B2 (en) * | 2006-10-02 | 2011-07-26 | Abbott Laboratories | Method for pain treatment |
US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
WO2008115290A2 (en) | 2006-10-25 | 2008-09-25 | Revalesio Corporation | Methods of wound care and treatment |
US8609148B2 (en) | 2006-10-25 | 2013-12-17 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
US8784897B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of therapeutic treatment of eyes |
US8784898B2 (en) | 2006-10-25 | 2014-07-22 | Revalesio Corporation | Methods of wound care and treatment |
DE102006056740A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
DE102006056739A1 (de) * | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
WO2008070661A1 (en) * | 2006-12-04 | 2008-06-12 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
KR101152162B1 (ko) * | 2006-12-08 | 2012-07-10 | 에프. 호프만-라 로슈 아게 | 치환된 피리미딘 및 jnk 조절제로서 그의 용도 |
TW200904437A (en) | 2007-02-14 | 2009-02-01 | Janssen Pharmaceutica Nv | 2-aminopyrimidine modulators of the histamine H4 receptor |
US20080217501A1 (en) * | 2007-02-14 | 2008-09-11 | Chad Jensen | Power a-frame |
KR20090125155A (ko) | 2007-03-01 | 2009-12-03 | 추가이 세이야쿠 가부시키가이샤 | 마크로 고리상 화합물 |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
EP2727909A1 (en) | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
WO2008116185A2 (en) * | 2007-03-21 | 2008-09-25 | Neurocrine Biosciences, Inc. | Substituted pyrimidines as adenosine receptor antagonists |
CA2694275A1 (en) * | 2007-07-26 | 2009-01-29 | Novartis Ag | Organic compounds |
DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
CA2698929C (en) * | 2007-09-14 | 2016-01-19 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones |
CN101848893B (zh) | 2007-09-14 | 2012-06-06 | 奥梅-杨森制药有限公司 | 1,3-二取代的4-(芳基-x-苯基)-1h-吡啶-2-酮 |
ATE510827T1 (de) | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
AU2008316708A1 (en) * | 2007-10-25 | 2009-04-30 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
US20090263495A1 (en) * | 2007-10-25 | 2009-10-22 | Revalesio Corporation | Bacteriostatic or bacteriocidal compositions and methods |
MX2010005110A (es) | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
DE102007061764A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
DE102007061763A1 (de) * | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
DE102008008838A1 (de) | 2008-02-13 | 2009-08-20 | Bayer Healthcare Ag | Cycloalkoxy-substituierte 4-Phenyl-3,5-dicyanopyridine und ihre Verwendung |
WO2009114533A2 (en) * | 2008-03-10 | 2009-09-17 | Cornell University | Modulation of blood brain barrier permeability |
DE102008013587A1 (de) * | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
MX2010011856A (es) | 2008-05-01 | 2011-02-15 | Revalesio Corp | Composiciones y métodos para tratar trastornos digestivos. |
EP2297104B1 (de) | 2008-05-29 | 2013-08-07 | Bayer Intellectual Property GmbH | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
ES2597903T3 (es) * | 2008-07-29 | 2017-01-24 | Boehringer Ingelheim International Gmbh | 5-Alquinil-pirimidinas |
JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体の調節因子としての3−アザビシクロ[3.1.0]ヘキシル誘導体 |
US20100093714A1 (en) * | 2008-10-13 | 2010-04-15 | Devraj Chakravarty | AMIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
EP2346505B1 (en) | 2008-10-16 | 2014-04-23 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
CN102232074B (zh) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | 作为代谢性谷氨酸盐受体调节剂的吲哚和苯并噁嗪衍生物 |
DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
DE102009006602A1 (de) * | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
AU2010246607B2 (en) | 2009-05-12 | 2012-09-27 | Addex Pharma S.A. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
CA2784749C (en) | 2009-12-18 | 2017-12-12 | E. Premkumar Reddy | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
UY33199A (es) | 2010-01-26 | 2011-08-31 | Boehringer Ingelheim Int | 5-alquinil-pirimidinas. |
CA2789189A1 (en) | 2010-03-10 | 2011-09-15 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
ES2365960B1 (es) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
CN102985073B (zh) | 2010-05-07 | 2015-03-25 | 利发利希奥公司 | 用于增强生理性能和恢复时间的组合物和方法 |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
NZ606281A (en) | 2010-08-05 | 2014-09-26 | Univ Temple | 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitriles and uses thereof |
CN103347500A (zh) | 2010-08-12 | 2013-10-09 | 利发利希奥公司 | 用于治疗tau蛋白病的组合物和方法 |
US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
SG188548A1 (en) | 2010-09-22 | 2013-04-30 | Arena Pharm Inc | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
WO2012062759A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
CN103261195B (zh) | 2010-11-08 | 2015-09-02 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
ES2543050T3 (es) | 2011-02-28 | 2015-08-14 | Array Biopharma, Inc. | Inhibidores de serina/treonina quinasa |
CZ305457B6 (cs) * | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
AU2013216935C1 (en) | 2012-02-08 | 2017-12-14 | John Emmerson Campbell | Heteroaryl compounds and methods of use thereof |
KR102093526B1 (ko) | 2012-03-01 | 2020-03-25 | 어레이 바이오파마 인크. | 세린/트레오닌 키나제 억제제 |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
WO2014036015A1 (en) | 2012-08-27 | 2014-03-06 | Array Biopharma Inc. | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
CN103819400B (zh) * | 2013-09-16 | 2016-05-04 | 江西师范大学 | 一种多组分反应合成具有不对称结构1.4-二氢吡啶及其衍生物的方法 |
CN105814031A (zh) * | 2013-12-19 | 2016-07-27 | 阿彻丹尼尔斯米德兰德公司 | 呋喃-2,5-二甲醇和(四氢呋喃-2,5-二基)二甲醇的磺酸酯及其衍生物 |
HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
EA033889B1 (ru) | 2014-01-21 | 2019-12-05 | Янссен Фармацевтика Нв | Комбинация на основе лиганда sv2a и положительного аллостерического модулятора метаботропного глутаматергического рецептора 2 подтипа |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
AU2016220153B2 (en) * | 2015-02-17 | 2020-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
DK3258938T3 (da) | 2015-02-17 | 2021-02-01 | Univ Arizona State | Phenothiazinanaloger som mitokondrie terapeutiske midler |
CN108349891B (zh) | 2015-06-22 | 2022-04-05 | 艾尼纳制药公司 | 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐 |
CN107573332B (zh) * | 2016-07-05 | 2022-04-19 | 广州再极医药科技有限公司 | 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用 |
EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
EP3494119A4 (en) | 2016-07-29 | 2020-03-25 | Sunovion Pharmaceuticals Inc. | CONNECTIONS AND COMPOSITIONS AND USES THEREOF |
WO2018039077A1 (en) | 2016-08-25 | 2018-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
CN106632076B (zh) * | 2016-09-20 | 2019-04-30 | 中国药科大学 | 4,6-二苯基嘧啶类化合物、其制备方法和医药用途 |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
US10172856B2 (en) | 2017-04-06 | 2019-01-08 | Janssen Pharmaceutica Nv | 2,4-diaminopyrimidine derivatives as histamine H4 modulators |
JOP20190279A1 (ar) * | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
EP3661929B1 (en) | 2017-08-02 | 2021-07-14 | Sunovion Pharmaceuticals Inc. | Isochroman compounds and uses thereof |
CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
SG11202005962YA (en) | 2017-12-29 | 2020-07-29 | Guangzhou Maxinovel Pharmaceuticals Co Ltd | Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application |
CN110240593A (zh) * | 2018-03-09 | 2019-09-17 | 四川科伦博泰生物医药股份有限公司 | 取代芳胺化合物及其制备方法和用途 |
WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
CN111377873B (zh) * | 2018-12-28 | 2023-03-28 | 四川科伦博泰生物医药股份有限公司 | 氨基嘧啶化合物及其制备方法和用途 |
CN113166119B (zh) * | 2018-12-28 | 2024-01-05 | 四川科伦博泰生物医药股份有限公司 | 取代芳基化合物及其制备方法和用途 |
EP3904348A4 (en) * | 2018-12-28 | 2022-10-19 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | AMINOPYRIDINE COMPOUND, METHOD FOR PREPARATION AND USE |
CA3130849A1 (en) | 2019-03-14 | 2020-09-17 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
WO2021063852A1 (en) * | 2019-09-30 | 2021-04-08 | F. Hoffmann-La Roche Ag | Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996228A (en) | 1973-12-21 | 1976-12-07 | Societa' Farmaceutici Italia S.P.A. | Pyrimidinoaminoethyl ergoline derivatives |
GB9125001D0 (en) * | 1991-11-25 | 1992-01-22 | Ici Plc | Heterocyclic compounds |
JPH08134044A (ja) * | 1994-11-09 | 1996-05-28 | Nippon Shoji Kk | 新規ピリミジン化合物、中間体及びそれらの製造法 |
US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
JPH09301958A (ja) * | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
TW440563B (en) * | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
US5958934A (en) * | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
US5952331A (en) * | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
JPH11158073A (ja) * | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンa3拮抗剤 |
US6200977B1 (en) * | 1998-02-17 | 2001-03-13 | Tularik Inc. | Pyrimidine derivatives |
-
2001
- 2001-02-15 PL PL365140A patent/PL203805B1/pl not_active IP Right Cessation
- 2001-02-15 IL IL15091201A patent/IL150912A0/xx unknown
- 2001-02-15 ES ES01927670T patent/ES2240449T3/es not_active Expired - Lifetime
- 2001-02-15 CN CN01805468A patent/CN1438890A/zh active Pending
- 2001-02-15 WO PCT/EP2001/001679 patent/WO2001062233A2/en active IP Right Grant
- 2001-02-15 EP EP01927670A patent/EP1261327B1/en not_active Expired - Lifetime
- 2001-02-15 JP JP2001561300A patent/JP4064671B2/ja not_active Expired - Fee Related
- 2001-02-15 RU RU2002123338/15A patent/RU2277911C2/ru not_active IP Right Cessation
- 2001-02-15 AU AU54643/01A patent/AU780527B2/en not_active Ceased
- 2001-02-15 DE DE60110391T patent/DE60110391T2/de not_active Expired - Lifetime
- 2001-02-15 MX MXPA02008240A patent/MXPA02008240A/es active IP Right Grant
- 2001-02-15 KR KR10-2002-7011137A patent/KR100521735B1/ko not_active IP Right Cessation
- 2001-02-15 CA CA002398274A patent/CA2398274C/en not_active Expired - Fee Related
- 2001-02-15 BR BR0108611-1A patent/BR0108611A/pt not_active IP Right Cessation
- 2001-02-15 CZ CZ20023199A patent/CZ20023199A3/cs unknown
- 2001-02-15 YU YU63802A patent/YU63802A/sh unknown
- 2001-02-15 HU HU0300029A patent/HUP0300029A2/hu unknown
- 2001-02-15 NZ NZ520241A patent/NZ520241A/en unknown
- 2001-02-15 AT AT01927670T patent/ATE293962T1/de not_active IP Right Cessation
- 2001-02-18 JO JO200121A patent/JO2286B1/en active
- 2001-02-20 US US09/788,956 patent/US6586441B2/en not_active Expired - Fee Related
- 2001-02-20 PE PE2001000182A patent/PE20011259A1/es not_active Application Discontinuation
- 2001-02-22 AR ARP010100801A patent/AR035392A1/es unknown
- 2001-02-23 UY UY26598A patent/UY26598A1/es not_active Application Discontinuation
-
2002
- 2002-07-30 ZA ZA200206077A patent/ZA200206077B/en unknown
- 2002-08-14 HR HRP20020673 patent/HRP20020673A2/hr not_active Application Discontinuation
- 2002-08-22 NO NO20024006A patent/NO20024006D0/no not_active Application Discontinuation
- 2002-08-23 MA MA26788A patent/MA26878A1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
YU63802A (sh) | Modulatori adenozinskih receptora | |
YU96502A (sh) | Derivati benzotiazola | |
TW200612937A (en) | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide | |
IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
TWI340640B (en) | Combination, kit and pharmaceutical composition for treatment of parkinson's disease | |
TW200738242A (en) | Dihydropteridinones in the treatment of respiratory diseases | |
GB0421639D0 (en) | Methods and compositions relating to alzheimer's disease | |
DE69840909D1 (de) | Analoge von kokain | |
PL1835924T3 (pl) | Leczenie choroby Parkinsona i zaburzeń związanych z tą chorobą z użyciem komórek uzyskiwanych po porodzie | |
SG161269A1 (en) | Personal care compositions comprising silicone resins with enhanced properties, method of manufacture, and method of use thereof | |
HUP0203198A2 (hu) | Tramadolvegyület és görcsoldó hatóanyagot tartalmazó gyógyászati készítmény, eljárás az előállítására és alkalmazása | |
DE69400799T2 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
TR199902291T2 (xx) | �kame edilmi� 4-Arilmetilen-2-imino-2, 3-dihidrotiazoller | |
WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
IL158631A (en) | 4-(phenyl-piperazinyl-methyl) benzamide derivatives, process for their preparation, compositions comprising them and use thereof for the manufacture of medicaments for the treatment of pain, anxiety or functional gastrointestinal disorders | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
IL159527A0 (en) | Human dr4 antibodies and uses thereof | |
IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
MXPA04004683A (es) | Derivados de benzotiazoles tal como ligandos de receptores de adenosina. | |
IL195431A0 (en) | Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia | |
PL378360A1 (pl) | Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju | |
IL174303A0 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
MXPA04001419A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson. |